Drug profile · INN
brimonidine tartrate
BRIMONIDINE TARTRATE
brimonidine tartrate (BRIMONIDINE TARTRATE) is a adrenergic receptor alpha-2 agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — brimonidine tartrate
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 1
- Programs
- 2
- Data quality
- 0.89
Quick answer
brimonidine tartrate (BRIMONIDINE TARTRATE) is a adrenergic receptor alpha-2 agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor alpha-2 agonist
Primary target: Adrenergic receptor alpha-2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is brimonidine tartrate?
brimonidine tartrate (BRIMONIDINE TARTRATE) is a adrenergic receptor alpha-2 agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for brimonidine tartrate?
BRIMONIDINE TARTRATE is a marketed brand name for brimonidine tartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of brimonidine tartrate?
brimonidine tartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.